ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Preclinical

CJC-1295 (no DAC) / Mod GRF 1-29

CJC-1295 (no DAC) / Mod GRF 1-29

Also known as: Mod GRF 1-29, CJC-1295 without DAC, Modified GRF

Overview

Key Facts

Primary Goal: A short-acting GHRH analog with four amino acid substitutions that protect it from enzymatic degradation, resulting in a half-life of approximately 30 minutes

A short-acting GHRH analog with four amino acid substitutions that protect it from enzymatic degradation, resulting in a half-life of approximately 30 minutes. It produces acute GH pulses that more closely mimic natural physiology. Half-Life ~30 minutes Typical Dose 100–300 mcg Frequency 1-3 times daily Cycle Length 8-16 weeks

Dosing Information

Half-Life

~30 minutes

Typical Dose

100–300 mcg

Frequency

1-3 times daily

Cycle Length

8-16 weeks

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

Mod GRF 1-29 has been shown to produce significant acute GH pulses comparable to native GHRH but with improved metabolic stability. When combined with GHRPs such as ipamorelin, studies show synergistic GH release that can exceed either compound alone by 2-3 fold. It is one of the most commonly used GHRH analogs in peptide research.

Frequently Asked Questions

Common questions about CJC-1295 (no DAC) / Mod GRF 1-29

UK-Specific Information

Exclusive data points and guidance for UK residents using CJC-1295 (no DAC) / Mod GRF 1-29

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With